Developer docs
API playgroundTry for free, no card

Search company profiles

BRAINBox Solutions

Full company profile

uuid0000fxk

Namestring
BRAINBox Solutions
Legal namestring
BRAINBox Solutions, Inc.
Websiteurl
brainboxinc.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

BRAINBox Solutions, Inc. is a privately held Delaware C-corporation, headquartered in Richmond, Virginia, developing an AI-enabled, multi-modality diagnostic and prognostic platform for mild traumatic brain injury (concussion / mTBI). The company's lead product, BRAINBox TBI, combines a proprietary panel of patented blood biomarkers (including β-synuclein, GFAP, neurogranin, von Willebrand Factor, astrotactin-2, MT3, and NSE) with a tablet-based neurocognitive assessment and clinical data, fused through proprietary machine-learning algorithms into a single integrated BRAINBox TBI score. The test is designed to aid diagnosis of concussion up to 96 hours post-injury and to provide a prognostic report on the likelihood of post-concussive symptoms at 30 days and up to 3 months, with an additional variant under development for differential diagnosis of TBI vs. neurodegenerative dementias in elderly populations. The platform is intended to run on both a proprietary point-of-care instrument (being co-developed with Prolight Diagnostics' Psyros single-molecule-counting platform) and on standard laboratory systems, supported by a patent portfolio of 22-24 issued patents worldwide.

BRAINBox is pre-revenue and pre-commercial, with commercial launch contingent on FDA submission following completion of the HeadSMART II pivotal trial (more than 2,000 patients across 18+ U.S. sites plus planned UK and New Zealand expansion). The company received FDA Breakthrough Device Designation in June 2019 and is currently positioned for a U.S. regulatory submission with peer-reviewed evidence published in JAMA Network Open in October 2025. Capitalization totals approximately $34 million to date, drawn from a $23 million Series A (Bioventures Investors-led, 2020), an ongoing Series B (Genoa Ventures-led, targeting approximately $18.5 million), a $3.5 million NINDS SBIR grant for the geriatric program, plus prior Virginia Catalyst and GE-NFL Head Health Challenge grants.

The go-to-market model combines direct enterprise sales to emergency departments, Level I trauma centers, urgent care, and specialty clinics (under newly appointed Chief Product and Commercial Officer Richard H. Noel, May 2026), with platform-channel distribution through the Prolight Diagnostics POC partnership and a test-to-treat ecosystem built jointly with Oragenics pairing BRAINBox diagnostics with the ONP-002 intranasal therapeutic. The planned revenue model is an instrument-plus-consumables razor-and-blade structure, with pricing not yet publicly disclosed. BRAINBox was spun out of ImmunArray in October 2018, inheriting biomarker IP originally licensed from Johns Hopkins University School of Medicine (Jennifer Van Eyk and Allen Everett).

Short descriptiontext

BRAINBox Solutions is a pre-commercial, AI-enabled diagnostics company developing a multi-modality blood biomarker and neurocognitive test (BRAINBox TBI) to diagnose concussion and predict post-concussive symptom risk, targeting emergency departments, trauma centers, urgent care, sports medicine, military, and geriatric / pediatric populations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRichmond, United States
HQ citystring
Richmond
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
traumatic brain injury diagnostics, concussion diagnostic tests, blood biomarker panels, point of care diagnostics, neurocognitive assessment tools
Industry4 codes
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLACAMAL
Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery)
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code6 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Analytical Laboratory Instrument Manufacturing334516
  • Scientific Research and Development Services5417
SIC code4 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Concussion Diagnostics
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Diagnostic Instrument Sales
TypeHardware Sales
Description

Future revenue from sales/placement of the BRAINBox point-of-care instrument that runs TBI-associated blood-based biomarker panels. Targeted at emergency departments, urgent care, and outpatient clinical settings.

brainboxinc.com
2Consumables / Per-Test Reagent Cartridges
TypeUsage Based
Description

Recurring revenue from consumable biomarker test cartridges / lab-based panels used on the BRAINBox platform or standard laboratory systems. High-margin consumable stream supporting the installed base of instruments.

brainboxinc.com
3Strategic Platform / Co-Development Partnerships
TypeLicensing Royalties
Description

BRAINBox-funded development programs with platform partners (e.g., Prolight Diagnostics Psyros cartridge) and test-to-treat partnerships (e.g., Oragenics) creating joint development and potential future licensing / royalty revenue.

brainboxinc.com
4Pre-Commercial / No Current Product Revenue
TypeSubscription Recurring
Description

Company is pre-revenue and pre-commercial; commercial launch of BRAINBox TBI test is pending FDA submission following completion of the pivotal HeadSMART II trial (more than 2,000 patients). To date, capital has come from Series A, Series B, SBIR grants, NFL/GE Head Health Challenge grants, Virginia Catalyst, and other equity and grant funding.

brainboxinc.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Pricing not publicly disclosed — pre-commercial / awaiting FDA submission.
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based / Not publicly disclosed. Future commercial model is expected to combine instrument placement with recurring consumable/cartridge sales in clinical settings.

brainboxinc.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1BRAINBox TBI
Description

Company's lead multi-modality diagnostic and prognostic product that combines a panel of proprietary blood biomarkers with neurocognitive testing to deliver a single integrated score characterizing injury severity and post-concussive symptom risk.

brainboxinc.com
+1 more record
Core offering1 text field

BRAINBox Solutions develops AI-enabled, multi-modality diagnostic and prognostic tests for concussion (mild traumatic brain injury). The lead product, BRAINBox TBI, combines a proprietary panel of patented blood biomarkers with tablet-based neurocognitive testing, integrated via proprietary machine learning algorithms to produce a single diagnostic score (up to 96 hours from injury) and a prognostic report of post-concussive symptom likelihood at 30 days and 3 months. The platform is designed for deployment on a proprietary point-of-care instrument or standard laboratory systems, with product variants tailored to adult, geriatric, and pediatric populations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • HeadSMART II pivotal trial enrolled 2,000+ subjects across 18+ U.S. clinical sites (plus UK/NZ) to support FDA submission.
+4 more records
Product overview1 text field

BRAINBox Solutions is developing a single unified multi-modality diagnostic platform anchored by its lead product BRAINBox TBI, an AI-enabled concussion (mild traumatic brain injury) diagnostic and prognostic test that combines proprietary blood biomarker panels, neurocognitive testing, and clinical data into a single integrated score. The platform architecture spans multiple product variants addressing distinct patient populations: the adult BRAINBox TBI (lead, currently in pivotal HeadSMART II trial for FDA submission), the BRAINBox Geriatric TBI Test (equilibrated for elderly patients to differentiate TBI from dementia, NIH-funded), and the BRAINBox Pediatric TBI Test (in pilot/pivotal planning for 10-18 year olds). The platform is delivered through two instruments — a BRAINBox Point of Care Instrument for rapid bedside use (being integrated with Prolight Diagnostics' Psyros POC platform) and standard laboratory systems. BRAINBox is also building a test-to-treat ecosystem through a partnership with Oragenics to combine its diagnostic capabilities with ONP-002 intranasal therapeutic, and has secured FDA Breakthrough Device Designation for the BRAINBox TBI test.

Product and service2 records
1BRAINBox TBI
CategoryConcussion Diagnostics - Core Product
Description

AI-enabled, multi-modality diagnostic and prognostic test for concussion (mild traumatic brain injury). Combines a proprietary panel of patented blood biomarkers with tablet/mobile neurocognitive testing, integrated via proprietary AI algorithms to generate a single BRAINBox TBI score for diagnosis up to 96 hours from injury and a prognostic report of post-concussive symptom likelihood at 30 days and up to 3 months. Currently completing pivotal HeadSMART II trial (n>2,000) to support FDA submission.

2BRAINBox Point of Care Instrument
Scale indicator18 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagship Poc Technology PartnerTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

BRAINBox-funded collaboration with Prolight Diagnostics to integrate BRAINBox's TBI biomarkers into Prolight's Psyros single-molecule-counting point-of-care platform using a multiplex-enabled, dried-reagent cartridge. Initial evaluation demonstrated strong analytic performance across a unique combination of three brain injury biomarkers; the partners are advancing to evaluation of all three assays on a 260-patient sample bank from HeadSMART II. BRAINBox fully funds the next-phase program.

Strategic tierFlagship Test-To-Treat PartnerTypeStrategic or Co-development PartnerAnnounced on2025-02-10
Description

Strategic partnership to develop the first intranasal therapy for mTBI / concussion, creating a comprehensive 'trigger-to-treat' platform that combines BRAINBox's multi-marker/multi-modality diagnostic capabilities with Oragenics' intranasal therapeutic candidate ONP-002. BRAINBox's diagnostic tools are planned for use in upcoming Phase IIa trials for precise patient selection and real-time monitoring of therapeutic efficacy.

Strategic tierSupporting Pediatric Study PartnerTypeStrategic or Co-development PartnerAnnounced on2023-02-09
Description

Funded collaboration with USA Hockey to evaluate biomarkers in blood and saliva for concussion in elite girls and boys high school hockey players. The study supports BRAINBox's pediatric test development by providing objective evidence of neurocognitive changes due to head impacts.

Strategic tierCore Clinical Research PartnerTypeImplementation/ SI/ Consulting Partner
Description

Clinical collaboration partner on the NIH-funded HeadSMART Geriatrics trial under the leadership of Vice Chair of Emergency Medicine Damon Kuehl, MD. Site for the HeadSMART II pivotal trial in adult mTBI patients.

Strategic tierFlagship Clinical Research PartnerTypeImplementation/ SI/ Consulting Partner
Description

Baylor College of Medicine's Department of Emergency Medicine (Henry JN Taub) hosts Principal Investigator Dr. W. Frank Peacock IV, MD, FACEP, for the HeadSMART II pivotal trial and serves as a primary clinical research site.

Strategic tierCore Clinical Research SiteTypeImplementation/ SI/ Consulting Partner
Description

HeadSMART II clinical trial site under the leadership of Adam Singer, MD.

Strategic tierCore Clinical Research SiteTypeImplementation/ SI/ Consulting Partner
Description

HeadSMART II clinical trial site under the leadership of Danielle Sandsmark, MD, PhD.

Strategic tierSupporting Clinical Research SiteTypeImplementation/ SI/ Consulting Partner
Description

HeadSMART II clinical trial site under the clinical leadership of James d'Etienne, MD, FACEP, MBA.

Strategic tierCore Biomarker Ip PartnerTypeStrategic or Co-development Partner
Description

Licensing partner for novel protein biomarkers for the diagnosis and monitoring of therapy across acute brain injury. The VERACIS laboratory, a wholly owned subsidiary of ImmunArray USA, was located on the Johns Hopkins campus. Patent-protected biomarkers developed with Johns Hopkins researchers form a core part of BRAINBox's IP portfolio.

Strategic tierSupporting Technology PartnerTypeTechnology or Integration
Description

Quanterix and ImmunArray teaming up to address neurodegenerative disease: Quanterix gained access to ImmunArray's brain injury biomarker portfolio and ImmunArray gained access to Quanterix's digital biomarker technology (2016).

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
1Cytox
TypeEmerging player
Description

Emerging player in blood-based biomarker tests for neurodegenerative disease (Alzheimer's, Parkinson's). Comparable to BRAINBox's planned extension into neurodegenerative-disease differential diagnosis in elderly populations using overlapping biomarker panels.

TypeEmerging player
Description

Ultra-sensitive single-molecule-array biomarker detection platform used in neurology and TBI biomarker research (including prior collaboration with ImmunArray/BRAINBox). Competes with BRAINBox on biomarker detection sensitivity and on enabling research-grade and emerging clinical applications in brain injury and neurodegeneration.

TypeBroad incumbent
Description

Global diagnostic incumbent operating cobas and Elecsys immunoassay platforms plus the recently acquired LumiraDx POC business (where incoming BRAINBox CPO Richard Noel previously led integration). Competes with BRAINBox across both central-lab and POC channels and has the commercial scale to rapidly displace emerging TBI biomarker entrants.

TypeBroad incumbent
Description

Global in-vitro diagnostics company operating the BioFire molecular diagnostics platform. Previous employer of BRAINBox's incoming CPO. Competes broadly in clinical diagnostics including hospital and emergency-department settings where BRAINBox TBI would be deployed.

TypeBroad incumbent
Description

Major diagnostics and imaging company operating the ADVIA Centaur and Atellica immunoassay platforms used in central laboratories and emergency-department-adjacent settings. Competes with BRAINBox on established hospital lab channels for biomarker-based TBI testing.

TypeOthers
Description

Developer of high-sensitivity multiplexed biomarker detection platforms (Meso Scale Discovery / SECTOR instruments). Provides enabling biomarker detection technology used in TBI and neurology research and an indirect competitor/partner for biomarker-based clinical applications like BRAINBox TBI.

7Banyan Biomarkers
TypeDirect peer
Description

Direct competitor developing blood-based biomarker tests for traumatic brain injury (the proprietary BAI test). Most directly comparable to BRAINBox TBI in terms of product, indication, and clinical-trial-driven regulatory strategy. Banyan's TBI assets were acquired by Abbott, increasing competitive pressure from a much larger diagnostic incumbent.

TypeDirect peer
Description

POC platform developer of the Psyros single-molecule-counting instrument with multiplex-enabled dried-reagent cartridges. BRAINBox's POC technology partner and a comparable POC diagnostics player building biomarker-detection platforms for decentralized clinical settings.

9Abbott Diagnostics
TypeBroad incumbent
Description

Large diagnostic incumbent that acquired Banyan Biomarkers' TBI assets and operates the i-STAT point-of-care platform widely deployed in U.S. emergency departments. Competes with BRAINBox on hospital formulary access, POC deployment channels, and integrated chemistry/immunoassay platforms used in TBI workups.

10LumiraDx
TypeDirect peer
Description

Point-of-care diagnostic platform company (acquired by Roche in 2024) that built a POC platform combining immunoassay and molecular testing. Comparable to BRAINBox's planned POC instrument strategy and an analog for the commercial trajectory BRAINBox could pursue in the ED/urgent-care channel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BRAINBox Solutions

Concussion Diagnosticsbrainboxinc.com

BRAINBox Solutions is a pre-commercial, AI-enabled diagnostics company developing a multi-modality blood biomarker and neurocognitive test (BRAINBox TBI) to diagnose concussion and predict post-concussive symptom risk, targeting emergency departments, trauma centers, urgent care, sports medicine, military, and geriatric / pediatric populations.

What BRAINBox Solutions does

BRAINBox Solutions, Inc. is a privately held Delaware C-corporation, headquartered in Richmond, Virginia, developing an AI-enabled, multi-modality diagnostic and prognostic platform for mild traumatic brain injury (concussion / mTBI). The company's lead product, BRAINBox TBI, combines a proprietary panel of patented blood biomarkers (including β-synuclein, GFAP, neurogranin, von Willebrand Factor, astrotactin-2, MT3, and NSE) with a tablet-based neurocognitive assessment and clinical data, fused through proprietary machine-learning algorithms into a single integrated BRAINBox TBI score. The test is designed to aid diagnosis of concussion up to 96 hours post-injury and to provide a prognostic report on the likelihood of post-concussive symptoms at 30 days and up to 3 months, with an additional variant under development for differential diagnosis of TBI vs. neurodegenerative dementias in elderly populations. The platform is intended to run on both a proprietary point-of-care instrument (being co-developed with Prolight Diagnostics' Psyros single-molecule-counting platform) and on standard laboratory systems, supported by a patent portfolio of 22-24 issued patents worldwide.

BRAINBox is pre-revenue and pre-commercial, with commercial launch contingent on FDA submission following completion of the HeadSMART II pivotal trial (more than 2,000 patients across 18+ U.S. sites plus planned UK and New Zealand expansion). The company received FDA Breakthrough Device Designation in June 2019 and is currently positioned for a U.S. regulatory submission with peer-reviewed evidence published in JAMA Network Open in October 2025. Capitalization totals approximately $34 million to date, drawn from a $23 million Series A (Bioventures Investors-led, 2020), an ongoing Series B (Genoa Ventures-led, targeting approximately $18.5 million), a $3.5 million NINDS SBIR grant for the geriatric program, plus prior Virginia Catalyst and GE-NFL Head Health Challenge grants.

The go-to-market model combines direct enterprise sales to emergency departments, Level I trauma centers, urgent care, and specialty clinics (under newly appointed Chief Product and Commercial Officer Richard H. Noel, May 2026), with platform-channel distribution through the Prolight Diagnostics POC partnership and a test-to-treat ecosystem built jointly with Oragenics pairing BRAINBox diagnostics with the ONP-002 intranasal therapeutic. The planned revenue model is an instrument-plus-consumables razor-and-blade structure, with pricing not yet publicly disclosed. BRAINBox was spun out of ImmunArray in October 2018, inheriting biomarker IP originally licensed from Johns Hopkins University School of Medicine (Jennifer Van Eyk and Allen Everett).

BRAINBox Solutions firmographics

Firmographics
Name
BRAINBox Solutions
Legal name
BRAINBox Solutions, Inc.
Website
https://brainboxinc.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
BRAINBox Solutions is a pre-commercial, AI-enabled diagnostics company developing a multi-modality blood biomarker and neurocognitive test (BRAINBox TBI) to diagnose concussion and predict post-concussive symptom risk, targeting emergency departments, trauma centers, urgent care, sports medicine, military, and geriatric / pediatric populations.
Ownership category
akta.pro rank

Where BRAINBox Solutions is headquartered

Location

Headquarters

HQ city
Richmond
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BRAINBox Solutions business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Diagnostic Instrument Sales: Future revenue from sales/placement of the BRAINBox point-of-care instrument that runs TBI-associated blood-based biomarker panels. Targeted at emergency departments, urgent care, and outpatient clinical settings.
  2. Consumables / Per-Test Reagent Cartridges: Recurring revenue from consumable biomarker test cartridges / lab-based panels used on the BRAINBox platform or standard laboratory systems. High-margin consumable stream supporting the installed base of instruments.
  3. Strategic Platform / Co-Development Partnerships: BRAINBox-funded development programs with platform partners (e.g., Prolight Diagnostics Psyros cartridge) and test-to-treat partnerships (e.g., Oragenics) creating joint development and potential future licensing / royalty revenue.
  4. Pre-Commercial / No Current Product Revenue: Company is pre-revenue and pre-commercial; commercial launch of BRAINBox TBI test is pending FDA submission following completion of the pivotal HeadSMART II trial (more than 2,000 patients). To date, capital has come from Series A, Series B, SBIR grants, NFL/GE Head Health Challenge grants, Virginia Catalyst, and other equity and grant funding.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPricing not publicly disclosed — pre-commercial / awaiting FDA submission.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

BRAINBox Solutions product offering

Product offering

Core offering

BRAINBox Solutions develops AI-enabled, multi-modality diagnostic and prognostic tests for concussion (mild traumatic brain injury). The lead product, BRAINBox TBI, combines a proprietary panel of patented blood biomarkers with tablet-based neurocognitive testing, integrated via proprietary machine learning algorithms to produce a single diagnostic score (up to 96 hours from injury) and a prognostic report of post-concussive symptom likelihood at 30 days and 3 months. The platform is designed for deployment on a proprietary point-of-care instrument or standard laboratory systems, with product variants tailored to adult, geriatric, and pediatric populations.

Product overview

BRAINBox Solutions is developing a single unified multi-modality diagnostic platform anchored by its lead product BRAINBox TBI, an AI-enabled concussion (mild traumatic brain injury) diagnostic and prognostic test that combines proprietary blood biomarker panels, neurocognitive testing, and clinical data into a single integrated score. The platform architecture spans multiple product variants addressing distinct patient populations: the adult BRAINBox TBI (lead, currently in pivotal HeadSMART II trial for FDA submission), the BRAINBox Geriatric TBI Test (equilibrated for elderly patients to differentiate TBI from dementia, NIH-funded), and the BRAINBox Pediatric TBI Test (in pilot/pivotal planning for 10-18 year olds). The platform is delivered through two instruments — a BRAINBox Point of Care Instrument for rapid bedside use (being integrated with Prolight Diagnostics' Psyros POC platform) and standard laboratory systems. BRAINBox is also building a test-to-treat ecosystem through a partnership with Oragenics to combine its diagnostic capabilities with ONP-002 intranasal therapeutic, and has secured FDA Breakthrough Device Designation for the BRAINBox TBI test.

Differentiator

Problem solved

Functional benefit

Brands

  • BRAINBox TBI: Company's lead multi-modality diagnostic and prognostic product that combines a panel of proprietary blood biomarkers with neurocognitive testing to deliver a single integrated score characterizing injury severity and post-concussive symptom risk.
  • BRAINBox ATE Test

Products and services

  • BRAINBox TBI AI-enabled, multi-modality diagnostic and prognostic test for concussion (mild traumatic brain injury). Combines a proprietary panel of patented blood biomarkers with tablet/mobile neurocognitive testing, integrated via proprietary AI algorithms to generate a single BRAINBox TBI score for diagnosis up to 96 hours from injury and a prognostic report of post-concussive symptom likelihood at 30 days and up to 3 months. Currently completing pivotal HeadSMART II trial (n>2,000) to support FDA submission.
  • BRAINBox Point of Care Instrument

Quantifiable outcome

  • HeadSMART II pivotal trial enrolled 2,000+ subjects across 18+ U.S. clinical sites (plus UK/NZ) to support FDA submission.
  • +4 more outcomes

Companies that use BRAINBox Solutions

Customer profile

Segments6 records

Ideal customer profiles5 records

BRAINBox Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature7 records

BRAINBox Solutions partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship poc technology partner, flagship test-to-treat partner, supporting pediatric study partner, core clinical research partner, flagship clinical research partner, core clinical research site, supporting clinical research site, core biomarker ip partner and supporting technology partner.

  • Prolight Diagnosticsflagship poc technology partnerStrategic or Co-development Partner · 30 March 2026BRAINBox-funded collaboration with Prolight Diagnostics to integrate BRAINBox's TBI biomarkers into Prolight's Psyros single-molecule-counting point-of-care platform using a multiplex-enabled, dried-reagent cartridge. Initial evaluation demonstrated strong analytic performance across a unique combination of three brain injury biomarkers; the partners are advancing to evaluation of all three assays on a 260-patient sample bank from HeadSMART II. BRAINBox fully funds the next-phase program.
  • Oragenics, Inc. (NYSE American: OGEN)flagship test-to-treat partnerStrategic or Co-development Partner · 10 February 2025Strategic partnership to develop the first intranasal therapy for mTBI / concussion, creating a comprehensive 'trigger-to-treat' platform that combines BRAINBox's multi-marker/multi-modality diagnostic capabilities with Oragenics' intranasal therapeutic candidate ONP-002. BRAINBox's diagnostic tools are planned for use in upcoming Phase IIa trials for precise patient selection and real-time monitoring of therapeutic efficacy.
  • USA Hockeysupporting pediatric study partnerStrategic or Co-development Partner · 9 February 2023Funded collaboration with USA Hockey to evaluate biomarkers in blood and saliva for concussion in elite girls and boys high school hockey players. The study supports BRAINBox's pediatric test development by providing objective evidence of neurocognitive changes due to head impacts.
  • Carilion Clinic / Virginia Tech Carilion School of Medicinecore clinical research partnerImplementation/ SI/ Consulting PartnerClinical collaboration partner on the NIH-funded HeadSMART Geriatrics trial under the leadership of Vice Chair of Emergency Medicine Damon Kuehl, MD. Site for the HeadSMART II pivotal trial in adult mTBI patients.
  • Baylor College of Medicine (Dr. W. Frank Peacock, Principal Investigator)flagship clinical research partnerImplementation/ SI/ Consulting PartnerBaylor College of Medicine's Department of Emergency Medicine (Henry JN Taub) hosts Principal Investigator Dr. W. Frank Peacock IV, MD, FACEP, for the HeadSMART II pivotal trial and serves as a primary clinical research site.
  • Stony Brook Hospital (State University of New York) — Dr. Adam Singercore clinical research siteImplementation/ SI/ Consulting PartnerHeadSMART II clinical trial site under the leadership of Adam Singer, MD.
  • University of Pennsylvania — Dr. Danielle Sandsmarkcore clinical research siteImplementation/ SI/ Consulting PartnerHeadSMART II clinical trial site under the leadership of Danielle Sandsmark, MD, PhD.
  • John Peter Smith Hospital (Integrated Emergency Services) — Dr. James d'Etiennesupporting clinical research siteImplementation/ SI/ Consulting PartnerHeadSMART II clinical trial site under the clinical leadership of James d'Etienne, MD, FACEP, MBA.
  • Johns Hopkins University School of Medicine (Dr. Jennifer Van Eyk and Dr. Allen Everett)core biomarker ip partnerStrategic or Co-development PartnerLicensing partner for novel protein biomarkers for the diagnosis and monitoring of therapy across acute brain injury. The VERACIS laboratory, a wholly owned subsidiary of ImmunArray USA, was located on the Johns Hopkins campus. Patent-protected biomarkers developed with Johns Hopkins researchers form a core part of BRAINBox's IP portfolio.
  • Quanterixsupporting technology partnerTechnology or IntegrationQuanterix and ImmunArray teaming up to address neurodegenerative disease: Quanterix gained access to ImmunArray's brain injury biomarker portfolio and ImmunArray gained access to Quanterix's digital biomarker technology (2016).

Scale indicators18 records

Recent moves7 records

Expansion highlights8 records

BRAINBox Solutions competitors and assessment

Company assessment

Emerging players

  • Cytox: Emerging player in blood-based biomarker tests for neurodegenerative disease (Alzheimer's, Parkinson's). Comparable to BRAINBox's planned extension into neurodegenerative-disease differential diagnosis in elderly populations using overlapping biomarker panels.
  • Quanterix: Ultra-sensitive single-molecule-array biomarker detection platform used in neurology and TBI biomarker research (including prior collaboration with ImmunArray/BRAINBox). Competes with BRAINBox on biomarker detection sensitivity and on enabling research-grade and emerging clinical applications in brain injury and neurodegeneration.

Broad incumbents

  • Roche Diagnostics: Global diagnostic incumbent operating cobas and Elecsys immunoassay platforms plus the recently acquired LumiraDx POC business (where incoming BRAINBox CPO Richard Noel previously led integration). Competes with BRAINBox across both central-lab and POC channels and has the commercial scale to rapidly displace emerging TBI biomarker entrants.
  • bioMérieux: Global in-vitro diagnostics company operating the BioFire molecular diagnostics platform. Previous employer of BRAINBox's incoming CPO. Competes broadly in clinical diagnostics including hospital and emergency-department settings where BRAINBox TBI would be deployed.
  • Siemens Healthineers: Major diagnostics and imaging company operating the ADVIA Centaur and Atellica immunoassay platforms used in central laboratories and emergency-department-adjacent settings. Competes with BRAINBox on established hospital lab channels for biomarker-based TBI testing.
  • Abbott Diagnostics: Large diagnostic incumbent that acquired Banyan Biomarkers' TBI assets and operates the i-STAT point-of-care platform widely deployed in U.S. emergency departments. Competes with BRAINBox on hospital formulary access, POC deployment channels, and integrated chemistry/immunoassay platforms used in TBI workups.

Others

  • Meso Scale Diagnostics: Developer of high-sensitivity multiplexed biomarker detection platforms (Meso Scale Discovery / SECTOR instruments). Provides enabling biomarker detection technology used in TBI and neurology research and an indirect competitor/partner for biomarker-based clinical applications like BRAINBox TBI.

Direct peers

  • Banyan Biomarkers: Direct competitor developing blood-based biomarker tests for traumatic brain injury (the proprietary BAI test). Most directly comparable to BRAINBox TBI in terms of product, indication, and clinical-trial-driven regulatory strategy. Banyan's TBI assets were acquired by Abbott, increasing competitive pressure from a much larger diagnostic incumbent.
  • Prolight Diagnostics: POC platform developer of the Psyros single-molecule-counting instrument with multiplex-enabled dried-reagent cartridges. BRAINBox's POC technology partner and a comparable POC diagnostics player building biomarker-detection platforms for decentralized clinical settings.
  • LumiraDx: Point-of-care diagnostic platform company (acquired by Roche in 2024) that built a POC platform combining immunoassay and molecular testing. Comparable to BRAINBox's planned POC instrument strategy and an analog for the commercial trajectory BRAINBox could pursue in the ED/urgent-care channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

BRAINBox Solutions social profiles

Digital presence

BRAINBox Solutions compliance and trust

Trust signal

Compliance4 records

BRAINBox Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BRAINBox Solutions leadership team

Management profile

Number of profiles

Profiles11 records

BRAINBox Solutions funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BRAINBox Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BRAINBox Solutions

What does BRAINBox Solutions do?

BRAINBox Solutions develops AI-enabled, multi-modality diagnostic and prognostic tests for concussion (mild traumatic brain injury). The lead product, BRAINBox TBI, combines a proprietary panel of patented blood biomarkers with tablet-based neurocognitive testing, integrated via proprietary machine learning algorithms to produce a single diagnostic score (up to 96 hours from injury) and a prognostic report of post-concussive symptom likelihood at 30 days and 3 months. The platform is designed for deployment on a proprietary point-of-care instrument or standard laboratory systems, with product variants tailored to adult, geriatric, and pediatric populations.

Is BRAINBox Solutions a public or private company?

BRAINBox Solutions is a private company. It is classified as venture growth investor backed and is currently operating.

When was BRAINBox Solutions founded?

BRAINBox Solutions was founded in 2018. It employs 11 to 50 people.

Where is BRAINBox Solutions based?

BRAINBox Solutions is headquartered in Richmond, United States, in the North America region.

How does BRAINBox Solutions make money?

Four revenue lines are on record. Diagnostic Instrument Sales are the primary driver. The others are consumables / Per-Test Reagent Cartridges, strategic Platform / Co-Development Partnerships and pre-Commercial / No Current Product Revenue.

Who are BRAINBox Solutions's main competitors?

Emerging players on record are Cytox and Quanterix. Broad incumbents are Roche Diagnostics, bioMérieux, Siemens Healthineers and Abbott Diagnostics. Meso Scale Diagnostics is listed as an others. Direct peers are Banyan Biomarkers, Prolight Diagnostics and LumiraDx.

Does BRAINBox Solutions have an API?

No public API is recorded for BRAINBox Solutions.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkBRAINBox and Prolight sign supply agreement for concussion testsBRAINBox Solutions signed an agreement with Prolight Diagnostics to supply Psyros instruments and cartridges for its concussion diagnostic tests. The deal follows a feasibility study using 260 patient samples from BRAINBox's HeadSMART II trial, which showed strong performance. The companies aim to commercialize the tests for point-of-care settings.PR NewswireBRAINBox Solutions Announces Agreement with Prolight Diagnostics for Commercial Supply of Pyros® Devices for Delivery of BRAINBox Concussion Diagnostics/Prognostics at Point-of-CareBRAINBox Solutions announced an agreement with Prolight Diagnostics to supply Pyros instruments and cartridges for point-of-care delivery of its concussion diagnostic tests. The collaboration followed a feasibility study evaluating 260 patient samples, and the company plans to prepare for market launch of its TBI tests.Clinical Lab ProductsBRAINBox Solutions Secures Funding for TBI Point-of-Care DevicesBRAINBox Solutions secured strategic financing through equity funding and credit facilities from Pivotal Capital Partners and New Horizon Bank to accelerate the development of point-of-care and laboratory devices for traumatic brain injury diagnostics. The capital will be used to develop hardware and software for commercial devices and acquire pilot instruments, supporting a collaboration with Prolight Diagnostics on the Psyro PoC platform.BrainboxincBRAINBox Solutions Announces Strategic Financing to Advance Development of Point-of-Care Concussion Diagnostic/PrognosticsBRAINBox Solutions announced strategic financing from Pivotal Capital Partners and New Horizon Bank to advance point-of-care and lab-based devices for its concussion diagnostic tests. The funding will support development of advanced hardware and software, including pilot instruments, following a successful feasibility study with Prolight Diagnostics.PR NewswireBRAINBox Solutions Announces Strategic Financing to Advance Development of Point-of-Care Concussion Diagnostic/PrognosticsBRAINBox Solutions announced strategic financing from Pivotal Capital Partners and New Horizon Bank to advance point-of-care and lab-based devices for its concussion diagnostic tests. The funding will support development of advanced hardware and software and acquisition of pilot instruments, following a successful feasibility study with Prolight Diagnostics.PR NewswireTwo BRAINBox Solutions' SAB Members to Participate in Key Panel at ADLM Meeting on Biomarker Use in Mild Traumatic Brain Injury Diagnosis/PrognosisBRAINBox Solutions announced two SAB members will join an ADLM panel on biomarkers for mild traumatic brain injury on July 27. The session includes presentations on analytical requirements and the HeadSmart II trial, which involves over 2000 samples and supports a regulatory submission for the company's TBI diagnostic test.MarketScreenerProlight Diagnostics Signs Development Deal with BrainBox SolutionsProlight Diagnostics AB has signed a development deal with BrainBox Solutions. Prolight Diagnostics is a Sweden-based medical technology company that develops patient-close test systems for Point of Care Testing, focusing on the heart marker troponin.PR NewswireBRAINBox Solutions Announces Appointment of Richard H. Noel as Chief Product and Commercial OfficerBRAINBox Solutions announced the appointment of Richard H. Noel as Chief Product and Commercial Officer, a newly created position at the Richmond, Virginia-based company. Noel brings over 10 years of molecular and point-of-care diagnostics experience from Roche Diagnostics, LumiraDx, and bioMérieux, and previously scaled LumiraDx's North American point-of-care business from zero to $440 million in revenue within 24 months. He will lead commercial planning and launch efforts for the company's BRAINBox TBI concussion diagnostic tests, which are currently completing a pivotal clinical trial ahead of an anticipated FDA submission.PR NewswireBRAINBox Solutions Announces Expansion of Patent Portfolio Covering Diagnostic and Prognostic Technology for Concussion and Neurodegenerative Disease TestsBRAINBox Solutions announced the expansion of its patent portfolio with three additional patents issued by the USPTO for concussion and neurodegenerative disease diagnostic technology. The new patents cover specific biomarkers including β-synuclein, glial fibrillary acidic protein, neurogranin, von Willebrand Factor, and astrotactin-2, bringing the company's total to 22 issued patents worldwide. These patents support the company's clinical stage programs for developing the BRAINBox TBI tests and provide an intellectual property foundation for future tests targeting neurodegenerative diseases such as Parkinson's and Alzheimer's.